Results 1 - 10 of 22 : 1 2 3 Next
Mixed results in the clinic don't spell blockbuster potential.
Sepracor Diversifies to Sleep Better
With its two top drugs in decline, diversification was the only answer.
Getting a handle on your portfolio begins with getting a handle on your time.
This Year's Biggest Nasdaq Losers
These five stocks took big hits in 2007.
A little more Rodney Dangerfield. A little less Aretha Franklin.
FDA Knocks Neurocrine a Knuckle Sandwich
The FDA clobbers the drugmaker with another delay.
Medicare Whacks Oncology Drugs
It reduces the reimbursement rate for two drugs for lymphoma.
An Unlikely Chat With Your Doctor
J&J starts direct-to-consumer advertising of its drug-eluting stent. Can it really pay off?
InterMune trades a future royalty expense for cash.
It has reduced its sales team after government price cuts for one of its top drugs.
Legal Information © 1995 - 2008 The Motley Fool. All rights reserved.
Market Data provided by 
Terms & Conditions
RSS Headlines
Fool UK